ESR1 and breast cancer: Several drugs have been developed to target the ERα in the context of breast cancer but, while these drugs inhibit the ERα in the breast, they were found to stimulate its activity in the CNS (Halbreich and Kahn, 2000; Littleton-Kearney et al., 2002; Miller, 2002; Veenman, 2020).